Niraparib

DOT1L inhibitor SGC0946 and PARP inhibitors Olaparib, Niraparib, Veliparib, and Talazoparib were all purchased from TargetMol. For drug synergy studies, ovarian cancer cells (4000/well) were seeded in 96-well plates for overnight incubation and treated with different doses of inhibitors for 5 days. Cell viability was evaluated by measuring the 450 nm absorbance with the Cell Counting Kit-8 (CCK-8) (YEASEN, Shanghai, China). Each concentration was tested in triplicate. The IC50 value was calculated and performed in GraphPad Prism v8.0. Drug synergistic effects were calculated based on the CompuSyn software or SynergyFinder. CI < 1 indicated synergism, CI = 1 indicated additive effects, and CI > 1 indicated antagonism.

To determine 50% inhibitory concentration (IC50) values of Olaparib (AZD2281; TargetMol, USA), Niraparib (MK-4827; TargetMol, USA), Veliparib (T2591; TargetMol, USA), and Talazoparib (T6523, TargetMol, USA), we measured the cell proliferation rate using Cell Counting Kit-8 (CCK-8) (YEASEN, Shanghai, China). IC50 values were analyzed using GraphPad Prism Version 8.0.